Ranbaxy’s generic pharmaceuticals business in the U.S. has been suspended until it can correct violations at its factories in India and the United States that triggered a federal injunction.
Under the terms of a settlement reached with the U.S. Department of Justice, which described its investigation of the company as “groundbreaking,” the company is to bring its facilities in India and the United States in line with good industry practices. The federal injunction was filed against one of the largest pharmaceutical companies in India and its U.S. operations, headquarters in Princeton, New Jersey. The action does not appear to affect the company’s generic version of Lipitor. It has an agreement with Teva Pharmaceuticals’ U.S. arm for a portion of the profits from sales during Ranbaxy’s 180-day, first-to-file exclusivity period.